30 March 2021 - - US-based small molecule drug discovery and development company Exo Therapeutics, Inc has appointed Nagesh Mahanthappa, PhD, to the company's board of directors and Charles W. Roberts, MD, PhD, to the company's scientific advisory board, the company said.

Dr. Mahanthappa was most recently the founding employee, president and CEO of Scholar Rock, Inc.

During his eight-year tenure at Scholar Rock, Dr. Mahanthappa took the company public and led two distinct drug candidates into clinical testing. Prior to Scholar Rock, he held scientific, strategic and corporate development roles at Avila and Alnylam.

He completed his post-doctoral training at The Eunice Kennedy Shriver Center and Harvard Medical School after receiving his PhD in Neurobiology from the California Institute of Technology.

Dr. Mahanthappa received his B.A. in Biology and Chemistry from the University of Colorado, and his M.B.A. from the F.W. Olin Graduate School of Management at Babson College.

Dr. Roberts currently serves as the director of the St. Jude Comprehensive Cancer Center and as an executive vice president and a full member in the Department of Oncology of St. Jude Children's Research Hospital.

Dr. Roberts received his medical and doctoral degrees from Washington University School of Medicine in St. Louis, Missouri. He completed his pediatric residency and pediatric hematology/oncology fellowship at Boston Children's Hospital/Dana-Farber Cancer Institute.

Dr. Roberts has been elected to the Society for Pediatric Research, American Society of Clinical Investigation and American Pediatric Society.

Exo's experienced, collaborative and dedicated team is passionate about pioneering exosite science to unlock breakthrough therapeutics.

Dr. Mahanthappa joins Michael Bruce, PhD, Aaron Nelson, MD, PhD, of Novartis Venture Fund, and Tom Cahill, MD, PhD, of Newpath Partners on Exo's BOD. Dr. Roberts joins Professor Stuart Schreiber of the Broad Institute of MIT and Harvard, Professor Ben Cravatt, PhD, of the Scripps Research Institute, and Professor Ben Ebert, MD, PhD, of the Dana Farber Cancer Institute on Exo's SAB.